NASDAQ:RNA Avidity Biosciences (RNA) Stock Price, News & Analysis → Musk’s new company could top a trillion? (From Paradigm Press) (Ad) Free RNA Stock Alerts $39.64 -0.32 (-0.80%) (As of 06/14/2024 08:51 PM ET) Add Compare Share Share Today's Range$38.76▼$42.0050-Day Range$22.73▼$39.9652-Week Range$4.82▼$42.00Volume4.73 million shsAverage Volume1.25 million shsMarket Capitalization$3.79 billionP/E RatioN/ADividend YieldN/APrice Target$44.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends Get Avidity Biosciences alerts: Email Address Avidity Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside11.7% Upside$44.29 Price TargetShort InterestBearish11.31% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.38Based on 34 Articles This WeekInsider TradingSelling Shares$16.12 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.10) to ($3.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.41 out of 5 starsMedical Sector873rd out of 914 stocksPharmaceutical Preparations Industry411th out of 429 stocks 2.5 Analyst's Opinion Consensus RatingAvidity Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvidity Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about Avidity Biosciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.31% of the outstanding shares of Avidity Biosciences have been sold short.Short Interest Ratio / Days to CoverAvidity Biosciences has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Avidity Biosciences has recently decreased by 4.33%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAvidity Biosciences does not currently pay a dividend.Dividend GrowthAvidity Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNA. Previous Next 3.0 News and Social Media Coverage News SentimentAvidity Biosciences has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 34 news articles for Avidity Biosciences this week, compared to 3 articles on an average week.Search Interest24 people have searched for RNA on MarketBeat in the last 30 days. This is an increase of 41% compared to the previous 30 days.MarketBeat Follows12 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avidity Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,118,570.00 in company stock.Percentage Held by InsidersOnly 3.68% of the stock of Avidity Biosciences is held by insiders.Read more about Avidity Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Avidity Biosciences are expected to decrease in the coming year, from ($3.10) to ($3.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avidity Biosciences is -13.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avidity Biosciences is -13.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvidity Biosciences has a P/B Ratio of 5.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Avidity Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. About Avidity Biosciences Stock (NASDAQ:RNA)Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Read More RNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNA Stock News HeadlinesJune 16 at 6:20 AM | insidertrades.comArthur A. Levin Sells 40,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockJune 7, 2024 | insidertrades.comSarah Boyce Sells 28,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockJune 6, 2024 | insidertrades.comAvidity Biosciences, Inc. (NASDAQ:RNA) CEO Sarah Boyce Sells 28,000 SharesMay 22, 2024 | insidertrades.comArthur A. Levin Sells 5,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockMay 17, 2024 | insidertrades.comAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells $2,121,000.00 in StockJune 16 at 4:55 AM | americanbankingnews.comSarah Boyce Sells 164,233 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockJune 15 at 8:34 AM | americanbankingnews.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells 104,245 Shares of StockJune 15 at 2:52 AM | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) PT Raised to $45.00 at Bank of AmericaJune 15 at 1:30 AM | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Trading 4.2% Higher Following Analyst UpgradeJune 15 at 1:30 AM | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Sees Unusually-High Trading Volume After Analyst UpgradeJune 14 at 2:38 PM | seekingalpha.comAvidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' UpgradeJune 14 at 9:00 AM | prnewswire.comAvidity Biosciences to Participate in Upcoming Investor ConferenceJune 14 at 6:28 AM | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Reaches New 1-Year High After Analyst UpgradeJune 14 at 5:44 AM | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Hits New 12-Month High on Analyst UpgradeJune 14 at 4:04 AM | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Price Target Increased to $45.00 by Analysts at Chardan CapitalJune 13, 2024 | prnewswire.comAvidity Biosciences, Inc. Announces Pricing of Public Offering of Common StockJune 13, 2024 | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Price Target Increased to $45.00 by Analysts at Evercore ISIJune 12, 2024 | prnewswire.comAvidity Biosciences, Inc. Announces Proposed Public Offering of Common StockJune 12, 2024 | investors.comThe 'Impressive' Results That Sent Top 1% Avidity Biosciences To A RecordJune 12, 2024 | benzinga.comCasey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On WednesdayJune 11, 2024 | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Given "Buy" Rating at Needham & Company LLCJune 8, 2024 | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Trading Down 5.7% on Insider SellingMay 29, 2024 | finance.yahoo.comAvidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research CongressMay 29, 2024 | fool.com2 Potentially High-Reward Growth Stocks to Buy Right NowMay 23, 2024 | investorplace.comDip Then Rip? 3 Nasdaq Stocks to Buy Before the ReboundSee More Headlines Receive RNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/17/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RNA CUSIPN/A CIK1574111 Webwww.aviditybiosciences.com Phone858-401-7900FaxN/AEmployees253Year FoundedN/APrice Target and Rating Average Stock Price Target$44.29 High Stock Price Target$60.00 Low Stock Price Target$30.00 Potential Upside/Downside+11.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-212,220,000.00 Net Margins-2,103.78% Pretax Margin-2,103.78% Return on Equity-37.98% Return on Assets-33.09% Debt Debt-to-Equity RatioN/A Current Ratio12.47 Quick Ratio12.47 Sales & Book Value Annual Sales$9.56 million Price / Sales396.57 Cash FlowN/A Price / Cash FlowN/A Book Value$6.76 per share Price / Book5.86Miscellaneous Outstanding Shares95,640,000Free Float92,118,000Market Cap$3.79 billion OptionableOptionable Beta0.81 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Troy Edward Wilson J.D. (Age 55)Ph.D., Co-Founder & Independent Chairman Comp: $70kMs. Sarah Boyce (Age 52)President, CEO & Director Comp: $998.88kMr. Michael F. MacLean (Age 58)Chief Financial & Chief Business Officer Comp: $674.74kDr. W. Michael F. Flanagan Ph.D. (Age 61)Chief Scientific & Technical Officer Comp: $675.22kMs. Teresa McCarthy (Age 60)Chief Human Resources Officer Comp: $628.79kDr. Arthur A. Levin Ph.D. (Age 70)Distinguished Scientist, Strategic Leader & Director Comp: $304.69kMr. Eric B. Mosbrooker (Age 57)Chief Strategy Officer Comp: $45kProf. Mark E. Davis Ph.D.Scientific Founder, Member of Scientific Advisory Board and Member of Board of ManagersDr. Frank P. McCormick Ph.D. (Age 74)Scientific Founder & Member of Scientific Advisory Board Mr. Geoffrey M. Grande C.F.A.VP of Investor Relation & Corporate CommunicationMore ExecutivesKey CompetitorsPTC TherapeuticsNASDAQ:PTCTConstellation PharmaceuticalsNASDAQ:CNSTZogenixNASDAQ:ZGNXORIC PharmaceuticalsNASDAQ:ORICSolid BiosciencesNASDAQ:SLDBView All CompetitorsInsiders & InstitutionsSarah BoyceSold 164,233 sharesTotal: $6.58 M ($40.08/share)Arthur A LevinSold 40,000 sharesTotal: $1.40 M ($35.07/share)Michael F MacleanSold 104,245 sharesTotal: $3.72 M ($35.72/share)Sarah BoyceSold 28,000 sharesTotal: $767,760.00 ($27.42/share)Teachers Retirement System of The State of KentuckyBought 20,867 shares on 5/28/2024Ownership: 0.022%View All Insider TransactionsView All Institutional Transactions RNA Stock Analysis - Frequently Asked Questions Should I buy or sell Avidity Biosciences stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RNA shares. View RNA analyst ratings or view top-rated stocks. What is Avidity Biosciences' stock price target for 2024? 7 Wall Street analysts have issued 1 year price targets for Avidity Biosciences' stock. Their RNA share price targets range from $30.00 to $60.00. On average, they expect the company's stock price to reach $44.29 in the next year. This suggests a possible upside of 11.7% from the stock's current price. View analysts price targets for RNA or view top-rated stocks among Wall Street analysts. How have RNA shares performed in 2024? Avidity Biosciences' stock was trading at $9.05 at the start of the year. Since then, RNA shares have increased by 338.0% and is now trading at $39.64. View the best growth stocks for 2024 here. When is Avidity Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our RNA earnings forecast. How were Avidity Biosciences' earnings last quarter? Avidity Biosciences, Inc. (NASDAQ:RNA) announced its quarterly earnings results on Wednesday, May, 15th. The biotechnology company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.02. The biotechnology company earned $3.54 million during the quarter, compared to analysts' expectations of $7.09 million. Avidity Biosciences had a negative net margin of 2,103.78% and a negative trailing twelve-month return on equity of 37.98%. What ETFs hold Avidity Biosciences' stock? ETFs with the largest weight of Avidity Biosciences (NASDAQ:RNA) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Global X Genomics & Biotechnology ETF (GNOM), Simplify Propel Opportunities ETF (SURI), Morningstar US Small Growth (MSGR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO) and Harbor Disruptive Innovation ETF (INNO). What other stocks do shareholders of Avidity Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT). When did Avidity Biosciences IPO? Avidity Biosciences (RNA) raised $150 million in an initial public offering on Friday, June 12th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO. Who are Avidity Biosciences' major shareholders? Avidity Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (7.77%), Avoro Capital Advisors LLC (6.09%), Vanguard Group Inc. (4.02%), RA Capital Management L.P. (3.43%), Janus Henderson Group PLC (1.30%) and Alethea Capital Management LLC (0.80%). Insiders that own company stock include Arthur A Levin, Michael F Maclean, Rtw Investments, Lp, Sarah Boyce and W Michael Flanagan. View institutional ownership trends. How do I buy shares of Avidity Biosciences? Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RNA) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored(Free Workshop) Advanced “bug-out bag” hacks!“Do you have a ‘bug-out bag’ (survival kit) ready to grab-and-go when a disaster or other crisis strikes?” ...Warrior Life | SponsoredSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.